Your browser doesn't support javascript.
loading
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz, Sara A; Martin, Miguel; Symmans, W Fraser; Jung, Kyung Hae; Huang, Chiun-Sheng; Thompson, Alastair M; Harbeck, Nadia; Valero, Vicente; Stroyakovskiy, Daniil; Wildiers, Hans; Campone, Mario; Boileau, Jean-François; Beckmann, Matthias W; Afenjar, Karen; Fresco, Rodrigo; Helms, Hans-Joachim; Xu, Jin; Lin, Yvonne G; Sparano, Joseph; Slamon, Dennis.
Afiliação
  • Hurvitz SA; David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. Electronic address: SHurvitz@mednet.ucla.edu.
  • Martin M; Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, CiberOnc, GEICAM, Madrid, Spain.
  • Symmans WF; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Jung KH; Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Seoul, Korea.
  • Huang CS; National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Thompson AM; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Harbeck N; Breast Center, University of Munich (LMU), Munich, Germany.
  • Valero V; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Stroyakovskiy D; Moscow City Oncology Hospital 62, Moscow, Russia.
  • Wildiers H; Department of General Medical Oncology, University Hospitals Leuven, Leuven, Belgium.
  • Campone M; Centre René Gauducheau, St Herblain cedex, France.
  • Boileau JF; McGill University, Sir Mortimer B Davis Jewish General Hospital, Montreal, QC, Canada.
  • Beckmann MW; University Hospital Erlangen, Department of Obstetrics and Gynecology, Friedrich-Alexander-Universität Erlangen, Comprehensive Cancer Center Erlangen-Europäische Metropolregion Nuremberg, Erlangen, Germany.
  • Afenjar K; Translational Research in Oncology, Biopark, Paris, France.
  • Fresco R; Translational Research in Oncology, Luis Alberto de Herrera, Montevideo, Uruguay.
  • Helms HJ; F Hoffmann-La Roche, Basel, Switzerland.
  • Xu J; Genentech, San Francisco, CA, USA.
  • Lin YG; Genentech, San Francisco, CA, USA.
  • Sparano J; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
  • Slamon D; David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Lancet Oncol ; 19(1): 115-126, 2018 01.
Article em En | MEDLINE | ID: mdl-29175149
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores Tumorais / Carboplatina / Receptor ErbB-2 / Terapia Neoadjuvante / Taxoides / Anticorpos Monoclonais Humanizados / Trastuzumab / Maitansina Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Middle aged País/Região como assunto: America do norte / Asia / Europa Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores Tumorais / Carboplatina / Receptor ErbB-2 / Terapia Neoadjuvante / Taxoides / Anticorpos Monoclonais Humanizados / Trastuzumab / Maitansina Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Middle aged País/Região como assunto: America do norte / Asia / Europa Idioma: En Ano de publicação: 2018 Tipo de documento: Article